All In Biotech

Drug Trial Radar · NCT06223048

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma

Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 7, 2023

Primary completion

Nov 2024

Study completion Feb 2025

Sponsor

Lead sponsor
Amydis Inc.Industry
Sponsor type
Industry
First posted
Jan 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).

Conditions

  • Primary Open Angle Glaucoma

Interventions

  • AMDX-2011PDrug

    AMDX-2011P single bolus injection intravenous for diagnostic review

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AMDX-2011P Adverse Events ProfileTime frame: 8 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona · Recruiting

  • Global Research Management

    Glendale, California · Recruiting

  • Eye Research Foundation

    Newport Beach, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.